Fund moves
1MShares reported
2 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
NVCT · NASDAQ · Pharmaceutical Preparations
Nuvectis Pharma (NVCT) · oqro.io/stocks/NVCT · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$19.84−0.45 (−2.22%)
Close of Nov 19, 2026, vs Nov 18 · end-of-day
No open-market purchase by an insider of Nuvectis Pharma was filed in the last 90 days. The latest on record was on Jun 24, 2025.
Since 2022, Nuvectis Pharma insiders reported 136 open-market purchases and 1 sale on Forms 4 and 5, with purchases in 4 different years, most recently 2025.
No open-market sale by an insider of Nuvectis Pharma (NVCT) was filed with the SEC in the last 90 days.
No trade in Nuvectis Pharma (NVCT) was disclosed by a member of Congress in the last 12 months.
Nuvectis Pharma's next results are expected on Feb 9, 2027, before the market opens. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+232.3% (+$13.87) from Nov 19, 2025 to Nov 19, 2026 · adjusted daily closes
Adjusted close went from $5.97 on Nov 19, 2025 to $19.84 on Nov 19, 2026 (+232.3%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 1 13F position change for 1 quarter ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Fort Lee, Nj.
Last 12 months
+232.3%
Market value
$682M
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 2.54M shares sold short (7.4% of shares outstanding), +6.0% vs the previous count, 15.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
—
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $141M, at Sep 30, 2026
Net income, last 12 months
−$50.5M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 4, 2026.
Fund moves
2 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Insider buying
Traded Jun 20, 2025 · filed 4 days later
Since the trade +144.0% · S&P 500 +20.5% · to Nov 19
A major shareholder of Nuvectis Pharma paid $45K out of pocket for Nuvectis Pharma shares.
Traded Jun 17 – Jun 18, 2025 · largest single transaction ~$226K
Jun 18, 2025~$226K · 28K sh @ $8.05
DetailsOfficial recordJun 17, 2025~$44K · 5,399 sh @ $8.11
DetailsOfficial recordInsider buying
Traded May 12, 2025 · filed 1 day later
Since the trade +136.6% · S&P 500 +22.8% · to Nov 19
A major shareholder of Nuvectis Pharma paid $172K out of pocket for Nuvectis Pharma shares.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Nuvectis Pharma reported 136 open-market purchases and 1 sale since 2022; purchases in 4 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $1.93M11×11 trades | — |
| 2024 | $446K10×10 trades | $22K1×1 trade |
| 2023 | $3.74M49×49 trades | — |
| 2022 | $2.36M66×66 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
No Schedule 13D or 13G filing on NVCT over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Last results
Nov 4, 2026
Within the 30 days after it, until Dec 4, 2026
Next results, expected
Feb 9, 2027
before the market opens; the date can move until the company confirms it
Purchases after results
74%
92 of 125 insider purchases since 2022 came within 30 days after a results announcement
From Nuvectis Pharma's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Nuvectis Pharma's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 4,000 words.
all of our efforts and financial resources to organizing and staffing our company, business planning, raising capital, acquiring, discovering product candidates and securing related intellectual property rights and conducting research and development activities for our programs. We do not have any products approved for sale and have not generated any revenue from product sales. We may never be able to develop or commercialize a marketable product. We have not yet successfully completed any pivotal clinical trials, obtained any regulatory approvals, manufactured a commercial-scale drug, or conducted sales and marketing activities. Our focus has been on progressing the pipeline and executing financing activities to fund pipeline development.
Source: SEC EDGAR, Form 10-K filed Feb 11, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: 36.7% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (26.6% on ATS, 10.1% with other brokers), below its 26-week average of 39.7%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: SIGMA X2 (14.0%), MS POOL (ATS-4) (12.0%), UBS ATS (11.2%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Against the S&P 500 over the year
Since Nov 17, 2025, NVCT is up 226.3% and the index fund is up 7.5%: 219 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much NVCT moves
Beta 0.8 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).
Latest annual report filed Feb 11, 2026, compared with the one filed Feb 25, 2025. Read the filing
From time to time, we may become involved in legal proceedings arising in the ordinary course of our business, the resolution of which we do not anticipate would have a material adverse impact on our financial position, results of operations or cash flows. However, there is no certainty that any such future litigation that may arise would not have a material financial impact on our business. As of the date of this report, we were not a party to any material legal matters or claims.
Source: SEC EDGAR, Form 10-K filed Feb 11, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.